{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Urethral+Carcinoma&page=3", "query": { "condition": "Metastatic Urethral Carcinoma", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 60, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Urethral+Carcinoma&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Urethral+Carcinoma&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T17:21:01.316Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00479128", "title": "Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Urethral Cancer" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 80, "start_date": "2006-09-28", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-10-04T17:21:01.316Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00479128" }, { "nct_id": "NCT05756569", "title": "Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Squamous Cell Carcinoma", "Locally Advanced Bladder Carcinoma", "Malignant Renal Pelvis Neoplasm", "Malignant Ureter Neoplasm", "Malignant Urethral Neoplasm", "Metastatic Bladder Carcinoma", "Stage III Bladder Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Unresectable Bladder Carcinoma", "Urachal Adenocarcinoma", "Bladder Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Enfortumab Vedotin", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2023-09-26", "completion_date": "2027-12-16", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-04T17:21:01.316Z", "location_count": 4, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05756569" }, { "nct_id": "NCT01352962", "title": "Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urethral Neoplasms", "Neoplasms, Urethral", "Cancer of the Urethra", "Urethral Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2011-09-26", "completion_date": "2018-07-06", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-04T17:21:01.316Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01352962" }, { "nct_id": "NCT00082706", "title": "Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Urethral Cancer", "Urachal Cancer" ], "interventions": [ { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2003-04-23", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-10-04T17:21:01.316Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00082706" }, { "nct_id": "NCT02012699", "title": "Integrated Cancer Repository for Cancer Research", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreatic Cancer", "Thyroid Cancer", "Lung Cancer", "Esophageal Cancer", "Thymus Cancer", "Colon Cancer", "Rectal Cancer", "Gastrointestinal Stromal Tumors", "Anal Cancer", "Bile Duct Cancer", "Duodenal Cancer", "Gallbladder Cancer", "Gastric Cancer", "Liver Cancer", "Small Intestine Cancer", "Peritoneal Surface Malignancies", "Familial Adenomatous Polyposis", "Lynch Syndrome", "Bladder Cancer", "Kidney Cancer", "Penile Cancer", "Prostate Cancer", "Testicular Cancer", "Ureter Cancer", "Urethral Cancer", "Hypopharyngeal Cancer", "Laryngeal Cancer", "Lip Cancer", "Oral Cavity Cancer", "Nasopharyngeal Cancer", "Oropharyngeal Cancer", "Paranasal Sinus Cancer", "Nasal Cavity Cancer", "Salivary Gland Cancer", "Skin Cancer", "Central Nervous System Tumor", "Central Nervous System Cancer", "Mesothelioma", "Breast Cancer", "Leukemia", "Melanoma", "Sarcoma", "Unknown Primary Tumor", "Multiple Myeloma", "Ovarian Cancer", "Endometrial Cancer", "Vaginal Cancer", "Neuroendocrine Tumors", "Plasma Cell Dyscrasia", "Healthy Control" ], "interventions": [], "intervention_types": [], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "110 Years", "sex": "ALL", "summary": "19 Years to 110 Years" }, "enrollment_count": 999999, "start_date": "2013-11-01", "completion_date": "2099-12", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-10-04T17:21:01.316Z", "location_count": 42, "location_summary": "Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more", "locations": [ { "city": "Greenwood Village", "state": "Colorado" }, { "city": "Manchester", "state": "Connecticut" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "DeLand", "state": "Florida" }, { "city": "Orange City", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02012699" }, { "nct_id": "NCT00022191", "title": "Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Cancer", "Transitional Cell Cancer of the Renal Pelvis and Ureter", "Urethral Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "European Organisation for Research and Treatment of Cancer - EORTC", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 608, "start_date": "2001-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-12", "last_synced_at": "2026-10-04T17:21:01.316Z", "location_count": 58, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 37 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00022191" }, { "nct_id": "NCT03288545", "title": "A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Transitional Cell", "Urinary Bladder Neoplasms", "Urologic Neoplasms", "Renal Pelvis Neoplasms", "Urothelial Cancer", "Ureteral Neoplasms", "Urethral Neoplasms" ], "interventions": [ { "name": "enfortumab vedotin (EV)", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 348, "start_date": "2017-10-11", "completion_date": "2026-02-20", "has_results": false, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-10-04T17:21:01.316Z", "location_count": 83, "location_summary": "Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 75 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03288545" }, { "nct_id": "NCT00942331", "title": "Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Urothelial Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Prostate Carcinoma", "Metastatic Renal Pelvis Urothelial Carcinoma", "Metastatic Ureter Urothelial Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Stage IV Bladder Urothelial Carcinoma AJCC v7", "Stage IV Prostate Cancer AJCC v7", "Stage IV Renal Pelvis Cancer AJCC v7", "Stage IV Ureter Cancer AJCC v7", "Stage IV Urethral Cancer AJCC v7", "Unresectable Urothelial Carcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Placebo Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 506, "start_date": "2009-07-15", "completion_date": "2021-06-15", "has_results": true, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-10-04T17:21:01.316Z", "location_count": 872, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 529 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Fairbanks", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00942331" }, { "nct_id": "NCT03291028", "title": "Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Renal Cell Carcinoma", "Urothelial Carcinoma", "Bladder Cancer", "Ureter Cancer", "Urethral Cancer" ], "interventions": [ { "name": "Immune checkpoint inhibitor targeting PD1", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 15, "start_date": "2017-11-27", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-04T17:21:01.316Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03291028" }, { "nct_id": "NCT00072150", "title": "Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Bladder Cancer", "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Urethral Cancer", "Stage III Bladder Cancer", "Stage III Urethral Cancer", "Stage IV Bladder Cancer", "Stage IV Urethral Cancer", "Transitional Cell Carcinoma of the Bladder", "Ureter Cancer" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2003-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-05", "last_synced_at": "2026-10-04T17:21:01.316Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00072150" } ] }